Lupin’s arm recalls 51,006 bottles of Cefdinir for Oral Suspension

10 Jun 2024 Evaluate

Lupin’s U.S.-based arm -- Lupin Pharmaceuticals, Inc. is recalling 51,006 bottles of Cefdinir for Oral Suspension (250 mg/5 mL) due to 'defective container: lack of seal integrity'. Cefrine Oral Suspension is indicated for the treatment of a range of bacterial infections.

The affected lot has been manufactured at Lupin’s Mandideep-based plant and marketed in the U.S. by Baltimore-based Lupin Pharmaceuticals, Inc. The drug maker initiated the Class II nationwide (U.S.) voluntary recall on May 8 this year. 

As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2083.00 3.50 (0.17%)
30-Dec-2025 11:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.20
Dr. Reddys Lab 1268.00
Cipla 1487.25
Zydus Lifesciences 903.15
Lupin 2083.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×